• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    NANOBIOTIX Announces First Data From Phase 1 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Esophageal Cancer

    10/1/25 4:15:00 PM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NBTX alert in real time by email
    • Treatment was well-tolerated and injection feasibility was confirmed in 13 patients with locally advanced adenocarcinoma of the esophagus
    • 85% (11/13) disease control rate (DCR)
    • 69% (9/13) objective response rate (ORR); 6 complete responses and 3 partial responses
    • Recruitment of 17 additional patients is ongoing as planned

    Data presented at the 2025 Annual Meeting of the American Society for Radiation Oncology (ASTRO) on October 1st

    PARIS and CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ:NBTX – the ‘‘Company''), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced first data from cohorts 1 and 2 of the dose escalation part of a Phase 1 dose escalation and dose expansion study evaluating JNJ-1900 (NBTXR3) combined with photon chemoradiation (cohort 1) or proton chemoradiation (cohort 2) followed by surgery, if medically indicated, for patients with locally advanced adenocarcinoma of the esophagus ("EADC"). The study is sponsored by The University of Texas MD Anderson Cancer Center ("MD Anderson") and results were presented by Principal Investigator Steven Lin, MD, PhD, Professor of Radiation Oncology at MD Anderson at the 2025 Annual Meeting of the American Society for Radiation Oncology (ASTRO).

    ABSTRACT # 1113: ENDOSCOPIC ULTRASOUND FINE NEEDLE INJECTION OF NBTXR3 ACTIVATED BY RADIOTHERAPY WITH CONCURRENT CHEMOTHERAPY FOR ADENOCARCINOMA OF THE ESOPHAGUS: FEASIBILITY AND SAFETY OF THE PHASE 1 DOSE ESCALATION PART FOR THE PHOTON-BASED COHORT

    Steven H. Lin, Emmanuel Coronel, Saumil Gandhi, Julianna Bronk, David Qian, Joe Y. Chang, Michael O'Reilly, Matthew Ning, Aileen Chen, Quynh Nguyen, James Welsh, Diana Amaya, Christina Hoang, Wayne Hofstetter, Mariela Blum-Murphy, Albert C. Koong, Zhongxing Liao

    MD Anderson Cancer Center, Houston, Texas, USA

    Esophageal cancer is the eighth most common cancer worldwide with an estimated 572,000 new cases and 508,600 deaths each year. Radiotherapy is a cornerstone of treatment and neoadjuvant chemoradiotherapy ("CRT") followed by surgery is the standard of care. However, there is some controversy as to whether the toxicities of neoadjuvant CRT will lead to increased postoperative complications. Moreover, surgical removal of large segments of the esophagus (esophagectomy) is associated with significant comorbidities and negative impact on patients' quality of life. Treatment strategies that enhance local control, reduce the need for surgery, and improve survival outcomes are an important unmet need.

    "Esophageal cancer remains one of the most difficult contexts for both patients and clinicians, where existing standards of care can create significant burdens for patients," said Louis Kayitalire, Chief Medical Officer at Nanobiotix. "We believe that JNJ-1900 (NBTXR3), through its broadly applicable mechanism of action, could offer a novel approach—one designed to enhance local control and potentially reduce the need for highly invasive procedures such as esophagectomy."

    Safety and Feasibility

    Treatment was well-tolerated and feasible in the study population (n=13):

    • Feasibility of endoscopic ultrasound-guided intratumoral injection was confirmed in 9 EADC patients with treated JNJ-1900 (NBTXR3) combined with photon CRT in cohort 1 and 4 EADC patients treated with JNJ-1900 (NBTXR3) combined with proton CRT in cohort 2
    • The recommended Phase 2 dose ("RP2D") for JNJ-1900 (NBTXR3) combined with photon CRT was established at 33% of gross tumor volume (GTV)
    • In total, 13 patients experienced treatment-emergent adverse events ("TEAEs") of any grade related to the overall treatment (Chemotherapy, RT, JNJ-1900 (NBTXR3), and injection procedure)
      • Of which, 6 patients experienced TEAEs of any grade (1, 2, or 3+) related to JNJ-1900 (NBTXR3) and 2 patient experienced TEAEs of any grade related to the injection procedure
        • Of these patients, 2 experienced grade 3+ TEAEs related to JNJ-1900 (NBTXR3) and 0 experienced grade 3+ TEAEs related to the injection procedure
    • No periprocedural or delayed adverse events were observed

    Signals of Efficacy

    Promising initial clinical response and outcomes:

    • 85% (11/13) disease control rate (DCR)
    • 69% (9/13) objective response rate (ORR), including 6 biopsy-confirmed complete responses (CRs) and 3 partial responses (PRs)
    • 6 patients in the study were medically indicated for and underwent surgery after treatment with CRT and JNJ-1900 (NBTXR3)
      • 2 of these patients had pathological complete response (pCR)
      • 4 of these patients had major pathologic response (≤10% viable cells)

    "These early results support our hypothesis that intratumoral injection of JNJ-1900 (NBTXR3) in combination with chemoradiation is both technically feasible and generally well-tolerated in patients with locally advanced esophageal adenocarcinoma," said Steven Lin, MD, PhD, Professor of Radiation Oncology at MD Anderson. "Importantly, we observed encouraging rates of disease control and complete response that suggest this novel approach could help improve local tumor control while potentially sparing patients from the risks and long-term consequences of esophagectomy. These early findings provide a strong foundation for further investigation."

    Importantly, this evaluation in locally advanced esophageal cancer could potentially open a new indication for JNJ-1900 (NBTXR3) and provide support for the investigational radioenhancer in combination with proton radiation therapy as an additional activation modality beyond standard (photon) radiation therapy. Recruitment for dose escalation cohort 1 is complete. 5 additional patients are being recruited for dose escalation cohort 2, which will be followed by recruitment of 12 additional patients for the dose expansion part of the study.

    About JNJ-1900 (NBTXR3)

    JNJ-1900 (NBTXR3) is a novel, potentially first-in-class oncology product composed of functionalized hafnium oxide nanoparticles that is administered via one-time intratumoral injection and activated by radiotherapy. Its proof-of-concept was achieved in soft tissue sarcomas through a successful randomized Phase 2/3 study in 2018. The product candidate's mechanism of action (MoA) is designed to induce significant tumor cell death in the injected tumor when activated by radiotherapy, subsequently triggering adaptive immune response and long-term anti-cancer memory. Given the physical MoA, Nanobiotix believes that JNJ-1900 (NBTXR3) could be scalable across any solid tumor that can be treated with radiotherapy and across any therapeutic combination, particularly immune checkpoint inhibitors.

    Radiotherapy-activated JNJ-1900 (NBTXR3) is being evaluated across multiple solid tumor indications as a single agent or combination therapy. The program is led by NANORAY-312—a global, randomized Phase 3 study in locally advanced head and neck squamous cell cancers. In February 2020, the United States Food and Drug Administration granted regulatory Fast Track designation for the investigation of JNJ-1900 (NBTXR3) activated by radiation therapy, with or without cetuximab, for the treatment of patients with locally advanced HNSCC who are not eligible for platinum-based chemotherapy—the same population being evaluated in the Phase 3 study.

    Given the Company's focus areas, and balanced against the scalable potential of NBTXR3, Nanobiotix has engaged in a collaboration strategy to expand development of the product candidate in parallel with its priority development pathways. Pursuant to this strategy, in 2019 Nanobiotix entered into a broad, comprehensive clinical research collaboration with The University of Texas MD Anderson Cancer Center to sponsor several Phase 1 and Phase 2 studies evaluating JNJ-1900 (NBTXR3) across tumor types and therapeutic combinations. In 2023, Nanobiotix announced a license agreement for the global co-development and commercialization of JNJ-1900 (NBTXR3) with Janssen Pharmaceutica NV, a Johnson & Johnson company.

    About NANOBIOTIX

    Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company's philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.

    Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.

    Nanobiotix is the owner of more than 25 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.

    For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter

    Disclaimer

    This press release contains "forward-looking" statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the use of proceed therefrom, and the period of time through which the Company's anticipates its financial resources will be adequate to support operations. Words such as "expects", "intends", "can", "could", "may", "might", "plan", "potential", "should" and "will" or the negative of these and similar expressions are intended to identify forward-looking statements. These forward-looking statements which are based on the Company' management's current expectations and assumptions and on information currently available to management. These forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those implied by the forward-looking statements, including risks related to Nanobiotix's business and financial performance, which include the risk that assumptions underlying the Company's cash runway projections are not realized. Further information on the risk factors that may affect company business and financial performance is included in Nanobiotix's Annual Report on Form 20-F filed with the SEC on April 2, 2025 under "Item 3.D. Risk Factors", in Nanobiotix's 2024 universal registration document filed with the AMF on April 2, 2025 under "chapter 1.5 Risk Factors", and subsequent filings Nanobiotix makes with the SEC and AMF from time to time, including the Half-Year Report at June 30, 2025 which are available on the SEC's website at www.sec.gov and on the AMF's website at www.amf.org. The forward-looking statements included in this press release speak only as of the date of this press release, and except as required by law, Nanobiotix assumes no obligation to update these forward-looking statements publicly.

    Contacts

    Nanobiotix
    Communications Department

    Brandon Owens

    VP, Communications

    +1 (617) 852-4835

    [email protected]


    Investor Relations Department


    Joanne Choi

    VP, Investor Relations (US)

    +1 (713) 609-3150

    [email protected]



    Ricky Bhajun

    Director, Investor Relations (EU)

    +33 (0) 79 97 29 99

    [email protected]



    Media Relations
    France – HARDY

    Caroline Hardy

    +33 06 70 33 49 50

    [email protected]   


    Global – uncapped Communications

    Becky Lauer

    +1 (646) 286-0057

    [email protected]



    Attachment

    • 2025-10-01 -- NBTX -- Ph1 NBTXR3 Data in EADC -- FINAL


    Primary Logo

    Get the next $NBTX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NBTX

    DatePrice TargetRatingAnalyst
    8/28/2024$12.00Buy
    Guggenheim
    12/8/2023$11.00Outperform
    Leerink Partners
    More analyst ratings

    $NBTX
    SEC Filings

    View All

    SEC Form 6-K filed by Nanobiotix S.A.

    6-K - Nanobiotix S.A. (0001760854) (Filer)

    10/1/25 4:15:05 PM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Nanobiotix S.A.

    6-K - Nanobiotix S.A. (0001760854) (Filer)

    9/30/25 4:19:43 PM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Nanobiotix S.A.

    6-K - Nanobiotix S.A. (0001760854) (Filer)

    9/30/25 4:15:03 PM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NBTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NANOBIOTIX Announces First Data From Phase 1 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Esophageal Cancer

    Treatment was well-tolerated and injection feasibility was confirmed in 13 patients with locally advanced adenocarcinoma of the esophagus85% (11/13) disease control rate (DCR)69% (9/13) objective response rate (ORR); 6 complete responses and 3 partial responsesRecruitment of 17 additional patients is ongoing as planned Data presented at the 2025 Annual Meeting of the American Society for Radiation Oncology (ASTRO) on October 1st PARIS and CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ:NBTX – the ‘‘Company''), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer

    10/1/25 4:15:00 PM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NANOBIOTIX Provides Business Update and Reports Half Year 2025 Financial Results

    PARIS and CAMBRIDGE, Mass., Sept. 30, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, provided an update on operational progress and announced its half year financial results for the six-month period ended June 30, 2025. Operational Highlights of the 2025 Half Year Period and To Date Expanding clinical development program evaluating the potential broad applicability of JNJ-1900 (NBTXR3) continues to build significant momentum: First patient dosed in the CONVERGE study, a Johnson & Johnson ("J&J")-sponsored randomized

    9/30/25 4:15:00 PM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 (NBTXR3) Plus Anti-PD-1 as a Potential New 1L or 2L+ Option in Anti-PD-1 Naïve or Resistant R/M-HNSCC

    Treatment remained well-tolerated with consistent injection feasibility in 103 heavily pre-treated patients with R/M-HNSCC naïve or resistant to anti-PD-163% (26/41) disease control rate ("DCR") and 37% (15/41) objective response rate ("ORR") in evaluable anti-PD-1 naïve patients per RECIST 1.174% (37/50) DCR and 32% (16/50) ORR in evaluable anti-PD-1 resistant patients per RECIST 1.115.5 months median Overall Survival ("mOS") in evaluable anti-PD-1 naïve patients11.4 months mOS in evaluable anti-PD-1 resistant patientsInvestigators concluded that these promising results warrant further exploration in randomized controlled trials Data presented as a "Top-rated Abstract in Head and Neck Can

    9/29/25 6:30:00 PM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NBTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on Nanobiotix with a new price target

    Guggenheim initiated coverage of Nanobiotix with a rating of Buy and set a new price target of $12.00

    8/28/24 7:51:18 AM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on Nanobiotix with a new price target

    Leerink Partners initiated coverage of Nanobiotix with a rating of Outperform and set a new price target of $11.00

    12/8/23 8:52:29 AM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NBTX
    Leadership Updates

    Live Leadership Updates

    View All

    NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024

    PARIS and CAMBRIDGE, Mass., June 12, 2024 (GLOBE NEWSWIRE) --  NANOBIOTIX (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that it will host a virtual KOL (Key Opinion Leader) event Tuesday June 18, 2024 at 9:00-10:30AM EDT / 3:00-4:30PM CEST. The event will feature several KOLs, including Study 1100 Coordinating Investigators Dr Colette Shen, MD, PhD and Dr Ari Rosenberg, MD, and Dr Jeffrey Bockman, PhD, will moderate the event. The KOLs will join Dr Sebastien Paris, PhD, from the Company to provide an in-depth review of NBTXR3 and the data recently presented at the

    6/12/24 4:15:00 PM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nanobiotix to Announce Half Year 2023 Financial Results on September 26, 2023

    PARIS and CAMBRIDGE, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that it will report its financial results for half-year ending June 30, 2023, on Tuesday, September 26, 2023, after the close of the US market. This release will be followed by a conference on Wednesday, September 27, 2023, at 8:00 AM EDT / 2:00 PM CEST. During the call, Laurent Levy, chief executive officer, and Bart van Rhijn, chief financial officer, will briefly review the Company's half-year results and provide an update on business activiti

    9/19/23 4:15:00 PM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NANOBIOTIX Strengthens Global Development Capabilities With the Appointment of Veteran Industry Leader Dr. Louis Kayitalire as Chief Medical Officer

    PARIS and CAMBRIDGE, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced the appointment of Louis Kayitalire, MD, as chief medical officer. Dr. Kayitalire brings an exceptional biopharmaceutical industry track record with proven success in the research, development, registration, and commercialization of therapeutics in oncology. "We are pleased to welcome Dr. Kayitalire to our executive leadership team at this pivotal moment for the development and commercialization of potential first-in-class radioenhancer NBTXR3," sa

    9/5/23 4:15:00 PM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NBTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Nanobiotix S.A. (Amendment)

    SC 13G/A - Nanobiotix S.A. (0001760854) (Subject)

    2/9/24 5:07:50 PM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Nanobiotix S.A. (Amendment)

    SC 13G/A - Nanobiotix S.A. (0001760854) (Subject)

    2/8/24 8:27:02 PM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Nanobiotix S.A. (Amendment)

    SC 13G/A - Nanobiotix S.A. (0001760854) (Subject)

    2/2/24 4:32:27 PM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NBTX
    Financials

    Live finance-specific insights

    View All

    NANOBIOTIX Announces New Results From a Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Combination With Immune Checkpoint Inhibitors as a 2L+ Therapy for Patients With Primary Cutaneous Melanoma Resistant to Anti-PD-1

    Data show a favorable safety profile and early efficacy signals in a heavily pre-treated population whose cancer progressed after multiple prior lines of therapy including anti-PD-1Recommended phase 2 dose (RP2D) established at 33% of gross tumor volume (GTV)47.4% (9/19) best observed objective response rate (ORR) in all lesions per RECIST 1.178.9% (15/19) best observed disease control rate (DCR) in all lesions per RECIST 1.114.6 months median Overall Survival (mOS) in all patients treated (n=21)Investigators concluded that these data warrant further investigation in randomized clinical trials as a potential new option for patients with primary cutaneous melanoma naïve or refractory to anti-

    9/17/25 4:15:00 PM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nanobiotix Announces Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer

    Results demonstrated favorable safety, injection feasibility, and encouraging oncologic outcomes in patients (n=22) with locally advanced or borderline resectable pancreatic cancerMedian Overall Survival of 23 months from date of diagnosis [95% CI; 17 months – not reached]Median Local Progression-Free Survival of 13.3 months from completion of radiationNotable findings observed in exploratory biomarker analyses include: An association between increased circulating tumor mutational burden (cTMB) and LPFS and OSCA19-9 normalization in 59% of patients in the study, and an association between CA19-9 normalization and OS First patient injected in a new cohort that adds standard-of-care concurre

    5/5/25 2:00:00 AM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference Call

    Full results from the completed dose escalation part and dose expansion parts of a Phase 1 study evaluating JNJ-1900 (NBTXR3) after induction chemotherapy for patients with locally advanced or borderline resectable pancreatic cancer to be presented by Principal Investigator Eugene Koay, MD, at ESTRO 2025 on Sunday, May 4th at 11:00 AM EDT / 5:00 PM CESTNanobiotix will host an event on Monday, May 5th at 8:00 AM EDT / 2:00 PM CEST to review the presented results PARIS and CAMBRIDGE, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ:NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expa

    4/30/25 2:00:00 AM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care